Genetic Counseling Referrals Rely on Genetic Report Examinations

News
Video

Suzanne Mahon, DNS, RN, AOCN, AGN-BC, FAAN, stated that it’s important to consider a patient’s family medical history when considering genetic counseling.

When a nurse practitioner looks at a somatic report, one of the first things that they need to consider is a patient’s past medical history, as well as their family medical history, according to Suzanne Mahon, DNS, RN, AOCN, AGN-BC, FAAN.

During the 2025 Oncology Nursing Society (ONS) Congress, Mahon, a clinical nurse specialist and professor emeritus at Saint Louis University, told CancerNetwork® that there are some cancer types that should be germline tested without hesitation, such as medullary thyroid cancer, triple negative breast cancer, metastatic prostate cancer, and pheochromocytomas. Just to name a few, she noted the NCCN guidelines have a more extensive list.

Additionally, it’s important to consider the pathology of the patient’s tumor. Mahon stated that if the disease has a gene alteration that is associated with germline risk, they need to be referred to a genetic counselor or oncologist for additional input. High variant alleles are also a reason to refer, she added. She concluded by saying that being asked by a patient to be tested can also be a valid enough reason to do so.

Transcript:

If you’re looking at a somatic report, [there are] things that you always need to do. First, no matter what, you need to look at the family and the patient’s history. Do they have one of those cancers that automatically should be germline tested—medullary thyroid cancer, pheochromocytomas, triple negative breast cancer, or metastatic prostate cancer? There’s a laundry list in the NCCN guidelines. If they have one of those cancers, whether you’ve done somatic biomarker testing or not, they’re an automatic referral. We need to get in the habit of doing a full 3-generation pedigree. If you just ask someone, “Oh, is there any cancer in your family?” We would all miss things. You have to systematically go through [their history]. How many siblings [do they have]? Are they alive? What is their health? We need to then look at that family history. Do they hit the criteria for testing based on personal or family history?

We also need to think about the pathology of their tumors. As I said, triple negative breast cancer, metastatic prostate cancer, and—the one that gets missed all the time—people who have 20 colon polyps over a lifetime, should be getting germline testing. If your patient hits any of those criteria, you need to automatically refer them [to be tested]. When you look at the somatic report, do they have an alteration in a gene associated with germline risk? That means you need to know which genes are potentially associated with germline risk, and if they are, even if it’s not concordant with the family history, that’s a reason to refer.

Finally, if they have a high variant allele frequency, especially in a gene associated with germline risk, that would be a reason to refer. I always say, “Listen to the patient”. If the patient is asking you, “Should I have testing to see if my kids are at risk?”—because that’s usually how the how the question gets asked—you have to listen to your patient and say, “We can explore that and not eliminate that.” Sometimes patients have a gut [feeling] they can’t quite explain to you, but it’s there.

Reference

Genetic testing for hereditary breast, ovarian, pancreatic, and prostate cancers. National Comprehensive Cancer Network. 2025. Accessed April 17, 2025. https://tinyurl.com/msfp7mve

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Related Content